ENTRY       D09013                      Drug
NAME        Teplizumab (USAN/INN);
            Teplizumab-mzwv;
            Tzield (TN)
PRODUCT     TZIELD (Provention Bio)
FORMULA     C6462H9938N1738O2022S46
EXACT_MASS  145709.5404
MOL_WEIGHT  145799.4725
SEQUENCE    (Heavy chain)
            QVQLVQSGGG VVQPGRSLRL SCKASGYTFT RYTMHWVRQA PGKGLEWIGY INPSRGYTNY
            NQKVKDRFTI SRDNSKNTAF LQMDSLRPED TGVYFCARYY DDHYCLDYWG QGTPVTVSSA
            STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
            LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPEAAGGP
            SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
            TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL
            TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
            QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
            (Light chain)
            DIQMTQSPSS LSASVGDRVT ITCSASSSVS YMNWYQQTPG KAPKRWIYDT SKLASGVPSR
            FSGSGSGTDY TFTISSLQPE DIATYYCQQW SSNPFTFGQG TKLQITRTVA APSVFIFPPS
            DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
            SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
            (Disulfide bridge: H22-H96, H146-H202, H263-H323, H369-H427, H228-H'228, H222-L213, L23-L87, L133-L193)
  TYPE      Peptide
REMARK      Product: D09013<US>
EFFICACY    Antidiabetic, Anti-CD3 antibody
  DISEASE   Type 1 diabetes [DS:H00408]
  TYPE      Monoclonal antibody
TARGET      CD3 [HSA:915 916 917] [KO:K06450 K06451 K06452]
  PATHWAY   hsa04658(915+916+917)  Th1 and Th2 cell differentiation
            hsa04659(915+916+917)  Th17 cell differentiation
            hsa04660(915+916+917)  T cell receptor signaling pathway
BRITE       USP drug classification [BR:br08302]
             Blood Glucose Regulators
              Antidiabetic Agents
               Glucose Control Agents, Other
                Teplizumab
                 D09013  Teplizumab (USAN/INN)
            Target-based classification of drugs [BR:br08310]
             Cell surface molecules and ligands
              Other cell surface molecules
               CD molecules
                CD3
                 D09013  Teplizumab (USAN/INN) &lt;US&gt;
            New drug approvals in the USA [br08319.html]
             New molecular entities and new therapeutic biological products
              D09013
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D09013
DBLINKS     CAS: 876387-05-2
            PubChem: 96025696
///
